Flavonoids as Therapeutic Agents in Alzheimer’s and Parkinson’s Diseases: A Systematic Review of Preclinical Evidences
Joint Authors
Júnior, Raimundo Gonçalves de Oliveira
Diniz, Tâmara Coimbra
Ribeiro, Fernanda P. R. A.
Oliveira, Ana Paula de
de Lavor, Érica Martins
de Andrade Teles, Roxana Braga
Gama e Silva, Mariana
Costa Pinto, Tiago Coimbra
Fernandes, Antonio Wilton Cavalcante
da Silva, Amanda Alves Marcelino
Cavalcante, Taisy Cinthia Ferro
Quintans Júnior, Lucindo José
Almeida, Jackson Roberto Guedes da Silva
Source
Oxidative Medicine and Cellular Longevity
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-21, 21 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-05-10
Country of Publication
Egypt
No. of Pages
21
Main Subjects
Abstract EN
Alzheimer’s and Parkinson’s diseases are considered the most common neurodegenerative disorders, representing a major focus of neuroscience research to understanding the cellular alterations and pathophysiological mechanisms involved.
Several natural products, including flavonoids, are considered able to cross the blood-brain barrier and are known for their central nervous system-related activity.
Therefore, studies are being conducted with these chemical constituents to analyze their activities in slowing down the progression of neurodegenerative diseases.
The present systematic review summarizes the pharmacological effects of flavonoids in animal models for Alzheimer’s and Parkinson’s diseases.
A PRISMA model for systematic review was utilized for this search.
The research was conducted in the following databases: PubMed, Web of Science, BIREME, and Science Direct.
Based on the inclusion criteria, 31 articles were selected and discussed in this review.
The studies listed revealed that the main targets of action for Alzheimer’s disease therapy were reduction of reactive oxygen species and amyloid beta-protein production, while for Parkinson’s disease reduction of the cellular oxidative potential and the activation of mechanisms of neuronal death.
Results showed that a variety of flavonoids is being studied and can be promising for the development of new drugs to treat neurodegenerative diseases.
Moreover, it was possible to verify that there is a lack of translational research and clinical evidence of these promising compounds.
American Psychological Association (APA)
de Andrade Teles, Roxana Braga& Diniz, Tâmara Coimbra& Costa Pinto, Tiago Coimbra& Júnior, Raimundo Gonçalves de Oliveira& Gama e Silva, Mariana& de Lavor, Érica Martins…[et al.]. 2018. Flavonoids as Therapeutic Agents in Alzheimer’s and Parkinson’s Diseases: A Systematic Review of Preclinical Evidences. Oxidative Medicine and Cellular Longevity،Vol. 2018, no. 2018, pp.1-21.
https://search.emarefa.net/detail/BIM-1211935
Modern Language Association (MLA)
de Andrade Teles, Roxana Braga…[et al.]. Flavonoids as Therapeutic Agents in Alzheimer’s and Parkinson’s Diseases: A Systematic Review of Preclinical Evidences. Oxidative Medicine and Cellular Longevity No. 2018 (2018), pp.1-21.
https://search.emarefa.net/detail/BIM-1211935
American Medical Association (AMA)
de Andrade Teles, Roxana Braga& Diniz, Tâmara Coimbra& Costa Pinto, Tiago Coimbra& Júnior, Raimundo Gonçalves de Oliveira& Gama e Silva, Mariana& de Lavor, Érica Martins…[et al.]. Flavonoids as Therapeutic Agents in Alzheimer’s and Parkinson’s Diseases: A Systematic Review of Preclinical Evidences. Oxidative Medicine and Cellular Longevity. 2018. Vol. 2018, no. 2018, pp.1-21.
https://search.emarefa.net/detail/BIM-1211935
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1211935